To access this element change to forms mode OFF
Grant Award View - GA187313
Rationalised inclusion of HDAC inhibitors with standard-of-care...
GA ID:
GA187313
Agency:
Department of Health and Aged Care
Approval Date:
7-Jun-2021
Publish Date:
30-Aug-2021
Category:
Health and Medical Research
Grant Term:
7-Jun-2021 to 31-May-2024
Value (AUD):
$614,017.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_Childhood_Cancer_Research
Grant Activity:
Rationalised inclusion of HDAC inhibitors with standard-of-care chemotherapy to improve outcomes for primary and relapsed neuroblastoma
Purpose:
Neuroblastoma is the most common cancer in infants, frequently occurring in children under two years of age. Approximately half of all neuroblastoma patients present with high-risk disease, and receive intense treatment including chemotherapy, surgery and radiotherapy. Despite this, the survival rate for high-risk neuroblastoma patients is still below 40-50 percent. Using advanced mathematical modelling we now propose to test a treatment regimen aimed at greatly improving this poor response rate.
GO ID:
GO Title:
MRFF – EPCDR Initiative – 2020 Childhood Cancer Research Grant Opportunity
Internal Reference ID:
MRF2007151
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, IRELAND